ERBB2 and breast cancer: For example, if the HER2- monoclonal antibody trastuzumab had been initially tested in unselected breast cancer patients, the therapeutic impact of trastuzumab may have been missed, as the benefit of trastuzumab is largely restricted to the 20-25% of breast cancer patients whose tumours overexpress HER2 [33].